Dermira Company Profile (NASDAQ:DERM)

About Dermira (NASDAQ:DERM)

Dermira logoDermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease, in multiple countries, including the United States. Glycopyrronium tosylate is a small molecule anticholinergic product for topical application for the treatment of primary axillary hyperhidrosis. Olumacostat glasaretil is a small molecule that targets sebum production following topical application for the treatment of acne.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:DERM
  • CUSIP: N/A
  • Web: www.dermira.com
Capitalization:
  • Market Cap: $1.22 billion
  • Outstanding Shares: 41,521,000
Average Prices:
  • 50 Day Moving Avg: $28.99
  • 200 Day Moving Avg: $31.12
  • 52 Week Range: $25.63 - $38.75
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.70
  • P/E Growth: -0.06
Sales & Book Value:
  • Annual Revenue: $23.65 million
  • Price / Sales: 51.62
  • Book Value: $9.76 per share
  • Price / Book: 3.01
Profitability:
  • EBIDTA: ($91,810,000.00)
  • Return on Equity: -30.71%
  • Return on Assets: -26.01%
Debt:
  • Current Ratio: 20.33%
  • Quick Ratio: 20.33%
Misc:
  • Average Volume: 521,462 shs.
  • Beta: 0.84
  • Short Ratio: 10.06
 
Frequently Asked Questions for Dermira (NASDAQ:DERM)

What is Dermira's stock symbol?

Dermira trades on the NASDAQ under the ticker symbol "DERM."

How were Dermira's earnings last quarter?

Dermira, Inc. (NASDAQ:DERM) posted its quarterly earnings results on Monday, November, 7th. The company reported ($0.72) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.72). The firm had revenue of $0.12 million for the quarter. View Dermira's Earnings History.

Where is Dermira's stock going? Where will Dermira's stock price be in 2017?

9 equities research analysts have issued 1-year price objectives for Dermira's shares. Their forecasts range from $40.00 to $48.00. On average, they expect Dermira's stock price to reach $43.80 in the next twelve months. View Analyst Ratings for Dermira.

What are analysts saying about Dermira stock?

Here are some recent quotes from research analysts about Dermira stock:

  • 1. Guggenheim analysts commented, "4Q16 results underscore that DERM continues to advance its pipeline of drugs that address large unmet needs in dermatology. Positive clinical data for DRM01 and DRM04 as well as solid execution in 4Q16, give us greater conviction in our positive investment thesis for the stock. We continue to think stock price appreciation will be driven by upward consensus earnings revisions to DERM's pipeline drug sales. We also view DERM as an attractive company in a consolidating industry." (3/2/2017)
  • 2. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (1/10/2017)

Who are some of Dermira's key competitors?

Who are Dermira's key executives?

Dermira's management team includes the folowing people:

  • Thomas G. Wiggans, Chairman of the Board, Chief Executive Officer, Co-Founder
  • William D. Young, Chairman of the Board
  • Christopher M. Griffith, Senior Vice President - Corporate Development and Strategy, Founder
  • Luis C. Pena, Co-Founder, Chief Development Officer
  • Andrew L. Guggenhime, Chief Financial Officer, Chief Operating Officer
  • Lori Lyons-Williams, Chief Commercial Officer
  • Eugene A. Bauer M.D., Founder, Chief Medical Officer, Director
  • Frederick B. Craves Ph.D., Lead Director, Independent Director
  • Emmanuel Caeymaex, Director
  • David E. Cohen M.D., Independent Director

How do I buy Dermira stock?

Shares of Dermira can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dermira's stock price today?

One share of Dermira stock can currently be purchased for approximately $29.40.


MarketBeat Community Rating for Dermira (NASDAQ DERM)
Community Ranking:  3.1 out of 5 (  )
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  181
MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Dermira (NASDAQ:DERM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Sell Ratings, 6 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $43.80 (48.98% upside)

Analysts' Ratings History for Dermira (NASDAQ:DERM)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/18/2017Needham & Company LLCReiterated RatingBuy$46.00LowView Rating Details
6/29/2017Evercore ISIInitiated CoverageOutperform$48.00MediumView Rating Details
6/22/2017Cantor FitzgeraldInitiated CoverageOverweight$45.00MediumView Rating Details
5/25/2017MizuhoLower Price TargetBuy -> Buy$42.00 -> $40.00LowView Rating Details
3/16/2017Raymond James Financial, Inc.Initiated CoverageUnderperform -> UnderperformHighView Rating Details
3/15/2017Citigroup Inc.Initiated CoverageUnderperformHighView Rating Details
3/2/2017GuggenheimReiterated RatingBuy -> Positive$40.00N/AView Rating Details
1/3/2017SEB Equity ResearchReiterated RatingReduceN/AView Rating Details
10/5/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
6/2/2016WedbushBoost Price TargetOutperform$42.00 -> $46.00N/AView Rating Details
8/19/2015Cowen and CompanyInitiated CoverageOutperform$40.00N/AView Rating Details
(Data available from 7/23/2015 forward)

Earnings

Earnings History for Dermira (NASDAQ:DERM)
Earnings by Quarter for Dermira (NASDAQ:DERM)
Earnings History by Quarter for Dermira (NASDAQ DERM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017Q4 2016($0.93)($0.21)$22.47 millionViewListenView Earnings Details
11/7/2016Q316($0.72)($0.72)$0.12 millionViewN/AView Earnings Details
8/8/2016Q2($0.86)($0.89)ViewN/AView Earnings Details
5/10/2016Q1($0.94)($0.95)ViewListenView Earnings Details
11/10/2015Q3($0.77)($0.58)$7.30 millionViewN/AView Earnings Details
8/13/2015Q2($0.81)($0.69)ViewN/AView Earnings Details
5/12/2015Q1($0.65)($0.57)ViewN/AView Earnings Details
3/25/2015Q4($0.59)($0.29)$7.30 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dermira (NASDAQ:DERM)
2017 EPS Consensus Estimate: ($3.88)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.84)($0.84)($0.84)
Q2 20171($0.81)($0.81)($0.81)
Q3 20171($1.00)($1.00)($1.00)
Q4 20171($1.23)($1.23)($1.23)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Dermira (NASDAQ:DERM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Dermira (NASDAQ:DERM)
Insider Ownership Percentage: 13.30%
Institutional Ownership Percentage: 84.58%
Insider Trades by Quarter for Dermira (NASDAQ:DERM)
Institutional Ownership by Quarter for Dermira (NASDAQ:DERM)
Insider Trades by Quarter for Dermira (NASDAQ:DERM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/5/2017Eugene A BauerInsiderSell2,500$30.00$75,000.00View SEC Filing  
7/3/2017Thomas G. WiggansCEOSell5,000$29.06$145,300.00View SEC Filing  
6/20/2017Eugene A BauerInsiderSell2,500$30.01$75,025.00View SEC Filing  
6/2/2017Thomas G. WiggansCEOSell5,000$27.52$137,600.00View SEC Filing  
5/15/2017Christopher M. GriffithSVPSell1,312$27.07$35,515.84View SEC Filing  
4/17/2017Christopher M. GriffithSVPSell1,303$33.97$44,262.91View SEC Filing  
4/3/2017Eugene A BauerInsiderSell2,500$33.53$83,825.00View SEC Filing  
4/3/2017Thomas G WiggansCEOSell8,000$33.49$267,920.00View SEC Filing  
4/3/2017William R RingoDirectorSell500$34.03$17,015.00View SEC Filing  
3/15/2017Christopher M. GriffithSVPSell1,303$35.79$46,634.37View SEC Filing  
3/1/2017Eugene A BauerInsiderSell2,500$33.61$84,025.00View SEC Filing  
3/1/2017Thomas G WiggansCEOSell11,000$33.54$368,940.00View SEC Filing  
3/1/2017William R RingoDirectorSell500$35.09$17,545.00View SEC Filing  
2/15/2017Christopher M. GriffithSVPSell1,303$30.79$40,119.37View SEC Filing  
2/15/2017William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
2/14/2017Eugene A BauerInsiderSell1,505$30.00$45,150.00View SEC Filing  
2/1/2017Eugene A BauerInsiderSell995$30.00$29,850.00View SEC Filing  
1/17/2017Christopher M. GriffithVPSell1,303$29.11$37,930.33View SEC Filing  
1/4/2017Thomas G WiggansCEOSell8,000$31.06$248,480.00View SEC Filing  
1/4/2017William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
1/3/2017Eugene A BauerInsiderSell2,500$30.07$75,175.00View SEC Filing  
12/16/2016William R RingoDirectorSell125$32.00$4,000.00View SEC Filing  
12/15/2016Christopher M. GriffithVPSell1,303$30.70$40,002.10View SEC Filing  
12/14/2016Eugene A BauerInsiderSell2,500$30.36$75,900.00View SEC Filing  
12/1/2016Thomas G WiggansCEOSell11,000$30.80$338,800.00View SEC Filing  
12/1/2016William R RingoDirectorSell375$32.00$12,000.00View SEC Filing  
11/9/2016Andrew GuggenhimeCFOSell4,100$35.02$143,582.00View SEC Filing  
11/9/2016William R RingoDirectorSell500$32.30$16,150.00View SEC Filing  
11/1/2016Thomas G WiggansCEOSell11,000$31.19$343,090.00View SEC Filing  
10/17/2016Christopher M GriffithVPSell1,303$32.33$42,125.99View SEC Filing  
10/11/2016Andrew GuggenhimeCFOSell10,900$34.34$374,306.00View SEC Filing  
10/3/2016Thomas G WiggansCEOSell11,000$34.60$380,600.00View SEC Filing  
10/3/2016William R RingoDirectorSell500$34.25$17,125.00View SEC Filing  
9/19/2016Andrew GuggenhimeCFOSell15,000$35.01$525,150.00View SEC Filing  
9/15/2016Christopher M GriffithVPSell1,303$33.26$43,337.78View SEC Filing  
9/12/2016Andrew GuggenhimeCFOSell10,000$32.53$325,300.00View SEC Filing  
9/1/2016Thomas G WiggansCEOSell11,000$31.63$347,930.00View SEC Filing  
9/1/2016William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
8/15/2016Christopher M GriffithVPSell1,303$31.75$41,370.25View SEC Filing  
8/11/2016Andrew GuggenhimeCFOSell10,000$31.02$310,200.00View SEC Filing  
8/1/2016Eugene A BauerInsiderSell2,500$33.18$82,950.00View SEC Filing  
8/1/2016Thomas G WiggansCEOSell11,000$33.19$365,090.00View SEC Filing  
8/1/2016William R RingoDirectorSell500$33.65$16,825.00View SEC Filing  
7/15/2016Christopher M GriffithVPSell1,303$30.02$39,116.06View SEC Filing  
7/11/2016Andrew GuggenhimeCFOSell10,000$30.15$301,500.00View SEC Filing  
7/5/2016Thomas G WiggansCEOSell11,000$29.62$325,820.00View SEC Filing  
7/1/2016Eugene A BauerInsiderSell2,500$29.48$73,700.00View SEC Filing  
6/23/2016Luis C PenaInsiderSell10,000$30.01$300,100.00View SEC Filing  
6/15/2016Luis C PenaInsiderSell10,000$29.47$294,700.00View SEC Filing  
6/13/2016Christopher M GriffithVPSell4,405$30.16$132,854.80View SEC Filing  
6/1/2016Eugene A BauerInsiderSell2,500$31.65$79,125.00View SEC Filing  
6/1/2016Thomas G WiggansCEOSell11,000$31.57$347,270.00View SEC Filing  
5/2/2016Eugene A BauerInsiderSell2,500$25.09$62,725.00View SEC Filing  
5/2/2016Thomas G WiggansCEOSell9,000$25.11$225,990.00View SEC Filing  
4/1/2016Eugene A BauerInsiderSell2,500$20.84$52,100.00View SEC Filing  
4/1/2016Thomas G WiggansCEOSell7,000$20.69$144,830.00View SEC Filing  
3/1/2016Eugene A BauerInsiderSell2,500$22.55$56,375.00View SEC Filing  
3/1/2016Thomas G WiggansCEOSell7,000$22.57$157,990.00View SEC Filing  
2/1/2016Eugene A BauerInsiderSell2,500$27.26$68,150.00View SEC Filing  
2/1/2016Thomas G WiggansCEOSell9,000$27.25$245,250.00View SEC Filing  
1/4/2016Eugene A BauerInsiderSell2,500$33.17$82,925.00View SEC Filing  
1/4/2016Thomas G WiggansCEOSell11,000$33.17$364,870.00View SEC Filing  
12/1/2015Eugene A BauerInsiderSell2,500$29.65$74,125.00View SEC Filing  
11/2/2015Eugene A BauerInsiderSell2,500$27.82$69,550.00View SEC Filing  
10/1/2015Eugene A BauerInsiderSell2,500$22.87$57,175.00View SEC Filing  
9/14/2015Eugene A BauerInsiderSell22,500$28.05$631,125.00View SEC Filing  
11/25/2014Matthew K FustDirectorBuy6,000$16.77$100,620.00View SEC Filing  
10/8/2014Bay City Capital LlcDirectorBuy69,112$16.00$1,105,792.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Dermira (NASDAQ:DERM)
Latest Headlines for Dermira (NASDAQ:DERM)
Source:
DateHeadline
finance.yahoo.com logoDermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : July 21, 2017
finance.yahoo.com - July 21 at 7:35 PM
americanbankingnews.com logoDermira, Inc. (NASDAQ:DERM) Given Buy Rating at Needham & Company LLC
www.americanbankingnews.com - July 18 at 1:18 PM
americanbankingnews.com logoDermira, Inc. (NASDAQ:DERM) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - July 17 at 12:33 PM
finance.yahoo.com logoETFs with exposure to Dermira, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 3:45 PM
finance.yahoo.com logoDermira, Inc. – Value Analysis (NASDAQ:DERM) : July 12, 2017
finance.yahoo.com - July 12 at 6:28 PM
finance.yahoo.com logoDermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : July 11, 2017
finance.yahoo.com - July 11 at 6:58 PM
americanbankingnews.com logoDermira, Inc. (DERM) Insider Sells $75,000.00 in Stock
www.americanbankingnews.com - July 6 at 8:06 PM
americanbankingnews.com logoInsider Selling: Dermira, Inc. (NASDAQ:DERM) CEO Sells 5,000 Shares of Stock
www.americanbankingnews.com - July 5 at 7:45 PM
americanbankingnews.com logoDermira, Inc. (NASDAQ:DERM) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - July 3 at 3:22 PM
americanbankingnews.com logoEvercore ISI Begins Coverage on Dermira, Inc. (DERM)
www.americanbankingnews.com - June 29 at 6:42 PM
streetinsider.com logoDermira (DERM) Reports Nonclinical Data Highlight the Role of Olumacostat Glasaretil in Sebum Inhibition
www.streetinsider.com - June 26 at 10:37 PM
reuters.com logoBRIEF-Dermira says findings from nonclinical studies evaluating mechanism of action for olumacostat glasaretil in sebum inhibition were published
www.reuters.com - June 26 at 10:37 PM
finance.yahoo.com logoNewly Published Nonclinical Data Highlight the Role of Olumacostat Glasaretil in Sebum Inhibition
finance.yahoo.com - June 26 at 5:34 PM
americanbankingnews.com logoAnalysts Offer Predictions for Dermira, Inc.'s FY2017 Earnings (DERM)
www.americanbankingnews.com - June 26 at 7:41 AM
americanbankingnews.com logoDermira, Inc. (DERM) Now Covered by Cantor Fitzgerald
www.americanbankingnews.com - June 22 at 2:58 PM
finance.yahoo.com logoDermira, Inc. breached its 50 day moving average in a Bullish Manner : DERM-US : June 22, 2017
finance.yahoo.com - June 22 at 10:24 AM
americanbankingnews.com logoEugene A. Bauer Sells 2,500 Shares of Dermira, Inc. (DERM) Stock
www.americanbankingnews.com - June 21 at 8:04 PM
americanbankingnews.com logoDermira, Inc. (DERM) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - June 20 at 10:30 AM
americanbankingnews.com logoDermira, Inc. (DERM) Raised to Hold at BidaskClub
www.americanbankingnews.com - June 15 at 6:58 PM
americanbankingnews.com logoThomas G. Wiggans Sells 5,000 Shares of Dermira Inc (DERM) Stock
www.americanbankingnews.com - June 5 at 10:19 PM
finance.yahoo.com logoDermira to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - May 30 at 4:38 PM
americanbankingnews.com logoShort Interest in Dermira Inc (DERM) Grows By 66.8%
www.americanbankingnews.com - May 28 at 7:02 AM
americanbankingnews.com logoDermira Inc (DERM) PT Lowered to $40.00
www.americanbankingnews.com - May 27 at 12:58 AM
americanbankingnews.com logoDermira Inc (DERM) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 26 at 10:50 AM
finance.yahoo.com logoTeva Pharma, Eagle Pharma, Depomed Among Slew Getting Price Haircuts
finance.yahoo.com - May 25 at 6:30 PM
americanbankingnews.com logoDermira Inc (DERM) Short Interest Up 2.9% in April
www.americanbankingnews.com - May 22 at 9:16 PM
finance.yahoo.com logoDERMIRA, INC. (DERM)
finance.yahoo.com - May 16 at 9:43 PM
americanbankingnews.com logoInsider Selling: Dermira Inc (DERM) SVP Sells 1,312 Shares of Stock
www.americanbankingnews.com - May 16 at 8:44 PM
finance.yahoo.com logoDermira Announces Closing of 3.00% Convertible Senior Notes Offering
finance.yahoo.com - May 16 at 4:42 PM
americanbankingnews.com logoDermira Inc (DERM) Expected to Earn Q2 2017 Earnings of ($0.81) Per Share
www.americanbankingnews.com - May 11 at 8:52 AM
finance.yahoo.com logoDermira Prices Offering of $250 Million of 3.00% Convertible Senior Notes
finance.yahoo.com - May 10 at 9:51 PM
finance.yahoo.com logoHere's Why Dermira Fell as Much as 18.7% This Morning
finance.yahoo.com - May 10 at 4:51 PM
americanbankingnews.com logoFY2020 EPS Estimates for Dermira Inc (DERM) Cut by Analyst
www.americanbankingnews.com - May 10 at 3:38 PM
finance.yahoo.com logoDermira Announces Proposed Offering of $250 Million of Convertible Senior Notes
finance.yahoo.com - May 9 at 4:41 PM
reuters.com logoBRIEF-Dermira qtrly net loss per share, basic, diluted $ 0.79
www.reuters.com - May 9 at 5:43 AM
nasdaq.com logoDermira Reports First Quarter 2017 Financial Results and Provides Corporate Update
www.nasdaq.com - May 9 at 5:43 AM
marketbeat.com logoDermira reports 1Q loss
marketbeat.com - May 8 at 5:36 PM
finance.yahoo.com logoDermira Reports First Quarter 2017 Financial Results and Provides Corporate Update 
finance.yahoo.com - May 8 at 4:30 PM
americanbankingnews.com logoDermira (DERM) Earning Somewhat Favorable Media Coverage, Study Finds
www.americanbankingnews.com - May 1 at 5:44 PM
americanbankingnews.com logoDermira Inc (DERM) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - May 1 at 2:24 PM
americanbankingnews.com logoDermira Inc (DERM) Expected to Announce Earnings of -$0.86 Per Share
www.americanbankingnews.com - May 1 at 10:04 AM
americanbankingnews.com logoDermira (DERM) Earning Somewhat Negative News Coverage, Report Finds
www.americanbankingnews.com - April 28 at 10:26 AM
americanbankingnews.com logoDermira (DERM) Given Coverage Optimism Score of 0.12
www.americanbankingnews.com - April 25 at 7:30 PM
americanbankingnews.com logoDermira (DERM) Getting Favorable News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 22 at 2:49 PM
finance.yahoo.com logoDermira, Inc. – Value Analysis (NASDAQ:DERM) : April 20, 2017
finance.yahoo.com - April 20 at 4:49 PM
finance.yahoo.com logoDermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : April 19, 2017
finance.yahoo.com - April 19 at 12:31 PM
americanbankingnews.com logoDermira (DERM) Getting Positive News Coverage, Study Shows
www.americanbankingnews.com - April 19 at 10:04 AM
americanbankingnews.com logoInsider Selling: Dermira Inc (DERM) SVP Sells 1,303 Shares of Stock
www.americanbankingnews.com - April 18 at 10:59 PM
americanbankingnews.com logoDermira (DERM) Earns Media Impact Rating of 0.30
www.americanbankingnews.com - April 16 at 9:08 AM
americanbankingnews.com logoDermira Inc (DERM) Expected to Post Earnings of -$0.86 Per Share
www.americanbankingnews.com - April 10 at 12:13 PM

Social

Chart

Dermira (DERM) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by MarketBeat.com Staff